Semax: Research Overview

The short version

Semax is a synthetic heptapeptide — a chain of seven amino acids — built from a small piece of adrenocorticotropic hormone (ACTH) with an extra three-amino-acid tail added to slow its breakdown in the body. Unlike full-length ACTH, it does not carry the steroidogenic activity that triggers cortisol release.

Researchers have studied Semax mainly in rodents, for its effects on neurotrophins — proteins such as BDNF and NGF that support the growth and survival of brain cells — and for possible protective effects after a stroke-like injury. In the United States, Semax is not an approved medicine; it is sold as an unscheduled research chemical. In Russia and Ukraine, it is registered as a prescription drug for ischemic stroke, transient ischemic attack, cognitive impairment, and optic-nerve disease.

The most common route in the cited literature is intranasal — sprayed into the nose rather than injected — though this page reports what a given study did, never a routine for a person to follow.

What it is

Semax is the linear heptapeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (one-letter code MEHFPGP), commonly supplied as the acetate salt. It combines the native ACTH(4-7) fragment (Met-Glu-His-Phe) with a C-terminal Pro-Gly-Pro tripeptide grafted on to slow enzymatic degradation and extend the molecule's activity in the body. Its several synonyms in the literature — ACTH(4-7)PGP, Met-ACTH(4-7)-Pro-Gly-Pro — all refer to the same construction.

Because it retains only a small fragment of the native hormone, Semax lacks the steroidogenic (cortisol-releasing) activity of full-length ACTH, which is the basis for describing it as a neuropeptide rather than a classical corticotropin. It has no approved indication in the United States.

How it works

In rodent brain, Semax rapidly and region-specifically upregulates the neurotrophins BDNF and NGF, and it increases BDNF protein in the basal forebrain after a single dose. Binding studies in rat basal-forebrain membranes describe a specific, reversible, calcium-dependent binding site with a dissociation constant of 2.4 nanomolar ^[4] — a tight, receptor-like affinity for a molecule with no formally named receptor.

Semax also acts on the endogenous opioid system, inhibiting enzymes that break down enkephalins, which is thought to prolong their natural signaling. In cerebral-ischemia models, its protective effect is described as dominated by an immunomodulatory and pro-vascular shift in brain gene expression — changes across large numbers of immune and vascular genes — rather than by a single, clean receptor mechanism ^[2].

What the research shows

Spinal-cord injury. In female mice with a T9-T10 spinal-cord injury, Semax improved functional recovery on standard locomotor tests and inhibited a cell-death pathway (pyroptosis) linked to lysosomal-membrane damage, acting on the mu-opioid-receptor gene Oprm1 through regulation of USP18 and the deubiquitination of the FTO protein ^[1].

Gene expression after stroke. Genome-wide transcriptional analysis after permanent middle-cerebral-artery occlusion in rats found Semax predominantly modulated immune-system genes — more than half of all affected genes, including immunoglobulins and chemokines — and altered vascular-system gene expression, with 24 genes affected at 3 hours and 12 at 24 hours. The authors frame immunomodulation and vascular regulation as the key mechanisms behind Semax's neuroprotection in this model ^[2].

Intranasal dosing and neurotrophin expression. A single 50 microg/kg intranasal dose of Semax in male rats produced rapid, gene- and region-specific changes: NGF and BDNF mRNA rose in the hippocampus, BDNF rose in the brainstem and cerebellum, while NGF mRNA fell in the frontal cortex — evidence that a single intranasal dose reaches and differentially affects several brain regions within hours ^[3].

Binding and BDNF protein. Intranasal Semax at 50 and 250 microg/kg produced a rapid, region-specific rise in basal-forebrain BDNF protein (but not cerebellar BDNF) three hours after dosing, alongside the specific, reversible, calcium-dependent binding site noted above ^[4].

Ischemia and memory. In a rat model of focal photoinduced prefrontal-cortex ischemia, six days of intranasal Semax decreased the volume of cortical infarction and improved retention of a learned avoidance response — an antiamnesic effect attributed to the neuroprotective action ^[5].

Reported effects, cautions & safety

Reported benefits (anecdotal, not clinical evidence): Across nootropics forums and biohacker writeups, the most consistent report is a quick-onset sense of mental "clarity" — thoughts feeling more organized, without the wired quality of a stimulant. People also describe sustained task focus, a stimulant-free lift in motivation and energy, and, less commonly, easier verbal fluency and a modest mood lift. A substantial minority report the opposite: a subtle-to-nonexistent effect, sometimes described as flat or 'depersonalized.'

Reported adverse effects (anecdotal, not clinical evidence): The most frequent complaint tied specifically to the studied intranasal route is transient nasal burning, stinging, or congestion, usually said to fade within ten to fifteen minutes. Users also describe a short overall duration of effect, afternoon or evening fatigue as it wears off, occasional headache, and — in a minority, particularly when stacked with stimulants — irritability or overstimulation.

Cited cautions from the literature:

• Unregulated sourcing. Semax sold in the US is an unscheduled research chemical with no required testing of identity, purity, or sterility; none of the pharmacology above was generated on consumer research-chemical product.
• Single-region evidence base. The bulk of human clinical experience with Semax comes from Russian and Ukrainian practice; there are no published Western randomized controlled trials, and most mechanistic data is from rodent models ^{[1][2][3][4][5]}.
• Nasal-lining irritation. The primary studied route is intranasal, which delivers the peptide across the nasal mucosa — the source of the burning and congestion reported above.
• Interaction unknowns. Semax engages serotonergic, dopaminergic, and endogenous-opioid signaling; combining it with stimulants, serotonergic antidepressants, or opioid-active drugs is unstudied.
• Powerful, incompletely understood gene-expression effects. Semax rapidly changes neurotrophin and, in injury models, large-scale immune-gene expression ^[1][2][3]; the consequences of repeating that in a healthy human brain over months or years have not been studied.
• No established human dosing framework. Every quantitative dose in the literature above is expressed per kilogram in rats or mice; there is no validated human dosing schedule outside Russian clinical formulations.

Where it fits in Cognitive & Nootropic research

Semax anchors the neuroprotection-and-cognition end of this desk, with the deepest injury-model evidence of the three compounds and a studied route — intranasal, at doses of 50 to 250 microg/kg in rodents — that ties directly into the nose-to-brain framing this desk is organized around ^[3][4]. Selank shares that same intranasal-delivery thread but is studied for anxiety rather than cognition; DSIP, the lead compound here, extends the thread into sleep research with a far less resolved mechanism. See the comparison page for how the three line up.